Pan-Asia Catalysts/Events, Quiddity Advisors

Travis Lundy

HK Type 4 license through Ballingal Investment Advisors Ltd. ("BIA" or "BIAL")

BACKGROUND
I have 20+yrs experience in Asia doing alternative strategies (i.e. non-delta1 non long-only) in fixed income, equity derivatives, and activist/catalyst/event-driven and long-short equity strategies with most of that time spent managing money. 

4 years in fixed income macro, 8 years running internal hedge fund and 4yrs investment banking at Citi in Japan, 3 years running an Asia multi-strat portfolio at a hedge fund, 4+yrs as an independent special situations analyst.

Pan-Asia Catalysts/Events

Quiddity Advisors

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sumitomo-pharma-co" target="_blank" data-smartkarma-citation="entities:1935:1" rel="noopener">Sumitomo Pharma (4506 JP)</a> is coming out of its earnings funk from 2023-2024. The stock has risen sharply off lows. Now the company has put out its hat.</li>
<li>They want to sell 59.0mm shares (against 385mm or so now) which is about 15% of shares out, and a whopping 65+% of (active voting rights) Max Real World Float.</li>
<li>There is index impact near-term and further out, and there are shorts to be covered. But this is heavily dilutive to the active Max Real World Float. </li>
</ul>



Sumitomo Pharma (4506 JP) is coming out of its earnings funk from 2023-2024. The stock has risen sharply off lows. Now the company has put out its hat.
They want to sell 59.0mm shares (against 385mm or so now) which is about 15% of shares out, and a whopping 65+% of (active voting rights) Max Real World Float.
There is index impact near-term and further out, and there are shorts to be covered. But this is heavily dilutive to the active Max Real World Float. 


【日本国内株式公開】住友製薬（4506 JP）投資目的株式300億円発行（2026年～2029年）